RELIGRAST 300MCG

Indications

• Neutropenia associated with chemotherapy
• Reduction in duration of neutropenia after myeloablative therapy followed by bone marrow transplantation
• Mobilisation of peripheral blood progenitor cells for autologous infusion
• Severe congenital neutropenia
• Persistent neutropenia in HIV infection

Dosage

Adults: For adults, filgrastim is typically administered as follows: 10 micrograms/kg daily, starting at least 24 hours after cytotoxic chemotherapy or within 24 hours of bone marrow infusion

Mechanism of action

Filgrastim acts by binding to the granulocyte-colony stimulating factor receptor (G-CSFR) on hematopoietic progenitor cells in the bone marrow. This binding stimulates the proliferation, differentiation, and activation of neutrophil precursors, leading to increased production and release of neutrophils into the bloodstream. Additionally, filgrastim enhances the survival and function of mature neutrophils.

Pharmacodynamics

Filgrastim enhances the myeloid lineage of hematopoiesis, promoting the formation of neutrophils, which are crucial for the immune response against infections. It has a pharmacodynamic profile characterized by a rapid increase in circulating neutrophil counts, typically observed within 24 hours after administration. The duration of action is influenced by the dosing regimen and the patient's response to treatment.

Pharmacokinetics

Filgrastim is administered via subcutaneous or intravenous routes. It has a volume of distribution of approximately 0.1 L/kg and a clearance rate of about 0.6 mL/min/kg. The half-life of filgrastim is approximately 3 to 4 hours, but it may vary based on individual patient factors and dosing. The drug is not metabolized in the liver and is primarily eliminated via renal pathways. Dosage adjustments may be necessary in patients with renal impairment.

Contra-indications

• Hypersensitivity to filgrastim or any of its components
• Severe congenital neutropenia with history of severe or recurrent infections
• Malignant myeloid conditions or pre-malignant myeloid conditions
• Sickle cell disease with crisis

Adverse effects

• Arthralgia
• Headache
• Dyspnoea
• Leukocytosis
• Spleen abnormalities
• Cutaneous vasculitis
• Pulmonary infiltrates leading to acute respiratory distress syndrome
• Capillary leak syndrome
• Hypoxia
• Pulmonary oedema
• Acute febrile neutrophilic dermatosis

Precautions

• Monitor for signs of splenomegaly and rupture during treatment
• Full blood counts including differential white cell and platelet counts should be monitored
• Patients with a history of pulmonary infiltrates or pneumonia may be at higher risk for acute respiratory distress syndrome

Pregnancy

Manufacturers advise avoiding use due to potential toxicity observed in animal studies.

Breast-feeding

There is no evidence for safe use during breastfeeding, and manufacturers advise avoiding their use.

Storage

Store in a refrigerator (2°C to 8°C). Do not freeze. Protect from light.

Formulations

• Subcutaneous injection
• Intravenous infusion

Indications

• Oral administration
• Topical application
• Intravenous infusion
• Preparation of injectable solutions
• Hydration in patients with fluid loss
• Dilution of concentrated solutions

Dosage

Children: Paediatric dosing for aqueous solutions should be determined based on the specific drug formulation and clinical condition. Refer to the BNF for Children for appropriate dosing guidelines.

Adults: Dosage of an aqueous solution is highly variable and depends on the specific drug concentration and the condition being treated. Refer to specific drug guidelines for accurate dosing.

Mechanism of action

The mechanism of action of aqueous solutions is primarily dependent on the active pharmaceutical ingredient (API) dissolved within them. The solvation of the drug in water enhances its bioavailability and facilitates transport across biological membranes, allowing for systemic or local therapeutic effects.

Pharmacodynamics

Pharmacodynamics of aqueous solutions is dictated by the characteristics of the dissolved drug. Factors such as the pH, ionic strength, and concentration of the solution can influence the drug's efficacy, potency, and duration of action. Aqueous solutions can enhance the solubility of poorly soluble compounds, leading to increased absorption and therapeutic effects.

Pharmacokinetics

Pharmacokinetics of aqueous solutions also varies with the active ingredient. Typically, the absorption of drugs from aqueous solutions occurs via passive diffusion or carrier-mediated transport across cell membranes. The distribution, metabolism, and excretion of the drug depend on its chemical properties, the presence of excipients, and individual patient factors.

Pregnancy

There are no specific data available regarding the safety of aqueous solutions in pregnancy; use only if clearly needed.

Breast-feeding

It is generally considered safe to use aqueous solutions while breastfeeding, but caution is advised.

Storage

Store in a cool, dry place away from direct sunlight. Ensure the container is tightly closed to prevent contamination.

Indications

• pH stabilization in laboratory experiments
• buffering during physiological studies
• preparation of samples for biochemical assays
• maintenance of pH in parenteral fluids

Dosage

Children: Refer to specific buffer formulations for detailed dosing guidance.

Adults: Refer to specific buffer formulations for detailed dosing guidance.

Mechanism of action

Buffers work by neutralizing added acids or bases through chemical reactions. For example, a buffer composed of acetic acid and sodium acetate can absorb excess hydrogen ions (from added acids) or donate hydrogen ions (to neutralize added bases), thus stabilizing the pH of the solution. This equilibrium is governed by the Henderson-Hasselbalch equation, which relates pH to the concentrations of the acidic and basic components of the buffer.

Pharmacodynamics

The pharmacodynamics of buffers involves their capacity to maintain pH levels within a target range, which is essential for various physiological processes. For instance, physiological buffers such as bicarbonate and phosphate play critical roles in maintaining the acid-base balance in the body, ensuring proper cellular function, enzyme activity, and metabolic processes.

Pharmacokinetics

The pharmacokinetics of buffer components depends on their specific chemical nature. Weak acids and bases used in buffers are typically absorbed and metabolized according to their molecular characteristics. For instance, bicarbonate can be reabsorbed in the kidneys and plays a significant role in systemic pH regulation. However, since buffer solutions are not typically absorbed in the same way as pharmaceutical drugs, their pharmacokinetic profiles are less relevant in a conventional sense.

Pregnancy

Buffering agents are generally considered safe during pregnancy; however, specific formulations should be evaluated for safety and efficacy.

Breast-feeding

Most buffering agents are considered safe during breastfeeding, but it is advisable to consult healthcare providers regarding specific formulations.

Storage

Store in a cool, dry place, away from direct sunlight and moisture. Follow specific storage instructions on the product label.

Dosage

Children: Refer to specific product guidelines as dosages may vary based on the active ingredient and clinical condition.

Adults: Refer to specific product guidelines as dosages may vary based on the active ingredient and clinical condition.

Mechanism of action

The specific mechanism of action for a concentrated drug depends on the active ingredients present in the formulation. Generally, concentrated drugs exert their effects by interacting with specific receptors or enzymes in the body, altering physiological processes. For example, concentrated analgesics may inhibit cyclooxygenase enzymes, leading to reduced production of prostaglandins, resulting in pain relief. Similarly, concentrated antibiotics may inhibit bacterial cell wall synthesis, leading to bacterial death.

Pharmacodynamics

Pharmacodynamics of concentrated drugs involves understanding the relationship between drug concentration at the site of action and the resulting therapeutic effect. Concentration-dependent effects may be observed, where higher concentrations lead to increased efficacy but also a risk of toxicity. The therapeutic window, which is the range between effective and toxic concentrations, is critical in guiding the safe use of concentrated formulations.

Pharmacokinetics

Pharmacokinetics of concentrated drugs encompasses absorption, distribution, metabolism, and excretion (ADME). Concentrated formulations may have altered pharmacokinetic profiles compared to standard formulations due to their higher potency. Absorption may be faster or more extensive, depending on the formulation. Distribution may be influenced by factors such as lipophilicity and plasma protein binding. Metabolism may occur in the liver, primarily through enzymatic pathways, while excretion typically occurs via renal or biliary routes.

Pregnancy

Consult a healthcare professional before use. Safety in pregnancy has not been established.

Breast-feeding

Consult a healthcare professional before use. Safety during breastfeeding has not been established.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.